The overexpression of human epidermal growth factor receptor 2 (HER2) in patients with urothelial carcinoma (UC) is linked to more aggressive disease and poor outcomes, but the genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood. To resolve this knowledge gap, a research team led by Xiaolin Zhu, MD, PhD, retrospectively analyzed 172 tumor samples from 162 patients with upper tract and muscle invasive UC using immunohistochemistry (IHC) and next-generation sequencing. ...
Urothelial Carcinoma Diagnostics
Advertisement
WGS-based ctDNA detection offered a median lead time of 131 days over radiographic imaging.
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
How can clinical tools like circulating tumor DNA inform bladder cancer treatment adjustments and transitions?
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Djaladat discusses how the presence of specific biomarkers, such as CK|V oncosomes and D|CK|V cells, correlate with RFS.
Patients with stage pT1 NMIBC who received transurethral resection of bladder tumor were included in the trial.
Liquid biopsy can benefit patients with UTUC by detecting rare events at higher incidences compared to tissue-based samples.
Researchers investigated the ability of variant histology to predict oncological outcomes.
Advertisement
Video Insights
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
